Viviane Brel[Author] - Search Results

Year	Number of Results
2008	1
2009	2
2011	2
2012	1
2015	1
2021	1
2024	0

1

Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition.

Lai LP, Brel V, Sharma K, Frappier J, Le-Henanf N, Vivet B, Muzet N, Schell E, Morales R, Rooney E, Basse N, Yi M, Lacroix F, Holderfield M, Englaro W, Marcireau C, Debussche L, Nissley DV, McCormick F. Lai LP, et al. Among authors: brel v. SLAS Discov. 2021 Aug;26(7):922-932. doi: 10.1177/24725552211008853. Epub 2021 Apr 24. SLAS Discov. 2021. PMID: 33896272 Free PMC article.

2

Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.

Beck J, Guminski Y, Long C, Marcourt L, Derguini F, Plisson F, Grondin A, Vandenberghe I, Vispé S, Brel V, Aussagues Y, Ausseil F, Arimondo PB, Massiot G, Sautel F, Cantagrel F. Beck J, et al. Among authors: brel v. Bioorg Med Chem. 2012 Jan 15;20(2):819-31. doi: 10.1016/j.bmc.2011.11.066. Epub 2011 Dec 8. Bioorg Med Chem. 2012. PMID: 22206869

3

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.

Tierny D, Serres F, Segaoula Z, Bemelmans I, Bouchaert E, Pétain A, Brel V, Couffin S, Marchal T, Nguyen L, Thuru X, Ferré P, Guilbaud N, Gomes B. Tierny D, et al. Among authors: brel v. Clin Cancer Res. 2015 Dec 1;21(23):5314-23. doi: 10.1158/1078-0432.CCR-14-3174. Epub 2015 Jul 13. Clin Cancer Res. 2015. PMID: 26169968 Clinical Trial.

4

Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.

Brel V, Annereau JP, Vispé S, Kruczynski A, Bailly C, Guilbaud N. Brel V, et al. Biochem Pharmacol. 2011 Dec 15;82(12):1843-52. doi: 10.1016/j.bcp.2011.08.028. Epub 2011 Sep 8. Biochem Pharmacol. 2011. PMID: 21924246

5

Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system.

Guminski Y, Grousseaud M, Cugnasse S, Brel V, Annereau JP, Vispé S, Guilbaud N, Barret JM, Bailly C, Imbert T. Guminski Y, et al. Among authors: brel v. Bioorg Med Chem Lett. 2009 May 1;19(9):2474-7. doi: 10.1016/j.bmcl.2009.03.052. Epub 2009 Mar 18. Bioorg Med Chem Lett. 2009. PMID: 19332372

6

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.

Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C. Barret JM, et al. Among authors: brel v. Cancer Res. 2008 Dec 1;68(23):9845-53. doi: 10.1158/0008-5472.CAN-08-2748. Cancer Res. 2008. PMID: 19047165

7

Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.

Kruczynski A, Mayer P, Marchand A, Vispé S, Fournier E, Annereau JP, Brel V, Barret JM, Delsol G, Imbert T, Fahy J, Bailly C. Kruczynski A, et al. Among authors: brel v. Anticancer Drugs. 2009 Jun;20(5):364-72. doi: 10.1097/CAD.0b013e32832a2ed9. Anticancer Drugs. 2009. PMID: 19322071

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year